Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of January 2020, with a specific report date of January 16, 2020. The registrant is a foreign private issuer based in Jerusalem, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate action rather than a financial statement.
Material Changes
On January 16, 2020, the Company executed an amendment to its warrant agent agreement with the Bank of New York Mellon. This amendment permits holders of all outstanding warrants issued during the Company's initial public offering on Nasdaq to exercise their warrants on a cashless basis.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the context of the warrant amendment. The document incorporates by reference the amendment agreement, a notice to warrant holders, and a press release dated January 16, 2020.
Investor Verification Checklist
- Verify the terms of the cashless exercise mechanism in the attached Amendment No. 1 to the ADS Warrant Agent Agreement (Exhibit 99.1).
- Confirm the specific notice provided to warrant holders regarding the new exercise rights (Exhibit 99.2).
- Review the press release dated January 16, 2020 (Exhibit 99.3) for additional context on the amendment.
- Note that this filing incorporates exhibits into the Company's Registration Statement on Form F-3 (Registration No. 333-201283).